Diabetes Advisory Council

advocacy-1142138-640x640If you ever wonder what happens after you attend MasterLab, offered by Diabetes Hands Foundation and a speaker asks a great question…

“How many of you know what your state’s Diabetes Action Plan is?”

Great question… and sitting there, I had no clue. I didn’t know.

This is what happens.

I went home and I did research, because I was curious. And then more research and I grew more curious. And I found out that in my state, they actually have a Diabetes Advisory Council that must have 3 people with diabetes in its ranks.

The Diabetes Advisory Council advises the state on diabetes prevention, diagnosis, education, care, treatment, impact, and costs. It helps to create the very Action Plan that the speaker mentioned.


I applied to be one of those three people.

And today, I can announce that I have been appointed by Governor Rick Scott to the Diabetes Advisory Council for the State of Florida.

Here’s the takeaway from all this…

  • Ask questions when your own answer is: “I don’t know.” You might be surprised at what you find.
  • Think about what you can do, no matter how big or how small, to make an impact. It’s not just the federal stuff that it’s important. It’s the local and the state stuff, too.
  • Reach for the seemingly impossible. (I certainly never expected to be appointed.)
  • Know that when the impossible happens, you can do it, because you have a community of people who support you as you support them.

If you had asked me three years ago if I was a diabetes advocate, I would have laughed in your face. I had no clue what being a diabetes advocate means. (And I thought: Who has time? Someone else will do advocacy. )

Today, without a doubt, I know the answer:

“I am a diabetes advocate.”

Everyone impacted by diabetes is a diabetes advocate. I am part of this amazing community of diabetes advocates.

I am so honored to help my community in the State of Florida and look forward to the opportunities to serve where I can.

Elle And Coach

040bf717d0da3d6a2fe11a0e36453408I thought that this would be an easy book to read and an easier review to write.

After all, Michael J. Fox explained:

“This book is so much more than a heartwarming story about a triumphant girl and her amazing dog. It’s a book about never giving up hope.”

I’ve read about hope. I’ve read about people with diabetes and their triumphs. Add a dog to the mix and even more entertaining. Easy.

I couldn’t get through the first chapter without sobbing. I had to put the book down and walk away. Once I got up the gumption to attempt a second chapter, I found myself wiping tears off the pages.

Stefan Shaheen, Elle’s mother, wrote this book about her daughter with help from Mark Dagostino, a NYT bestselling author, but it was Elle’s diary entries beginning the chapters that impacted me the most. Chapter 1, Diagnosis begins with:

“I was so scared. I actually thought I was going to die.” – Elle, age 12.

I don’t know what it’s like to have a child diagnosed with Type 1 diabetes, although The Kid is four and we don’t know what the future will bring.

I do know, however, what it’s like to feel sick and think you are going to die. I scribbled in my diary at twelve:

“I’m drinking a lot of OJ and water. A lot. I’m thirsty all the time. I’m tired all the time. I don’t know what’s wrong with me. I know I should tell my parents, but I’m scared.”

Reading of the days leading up to her diagnosis sent me back in time to my own pre-diagnosis days. For those of us who live with a chronic illness and can remember those days before, it’s a tough chapter, regardless of the chronic illness you have.

The lack of knowing what’s wrong, but knowing something is not right is universal when it comes to health. Elle’s attitude and her parents’ attitude were normal, because nothing is never normal again.

The second chapter was also difficult for me, because Shaheen delved into the statistics that I abhor. These statistics need to be shared and shouted, because diabetes is an invisible illness. Many of us work very hard to “look normal” and not let diabetes rule our lives, but the book eloquently shares how diabetes doesn’t care how you look or if you want a break. Elle’s first diaversary was also her first seizure.

I wanted to kiss Stephany when she shared her frustrations about daily life with diabetes and how disruptive it can be – and not in the way one would think. It’s not just checking blood glucose and ingredient lists; it’s hours arguing with insurance or pharmacies or ferrying supplies to different locations. It’s the constant nagging feeling in the back of your mind: “What’s the latest blood glucose? Did I give too much or not enough insulin? Where are the juice boxes?” It doesn’t stop. Ever.

The grin slowly grew as I read:

This cannot be as hard as it seems, I thought. It’s 2007, for crying out loud!

And then the grin faded as she shares the heartbreak of Elle apologizing for a low blood sugar. I apologize to John all the time when I’m low. It was painful to read the reaction from a loved one. I don’t get to see it from the other side.

Elle does get a service dog named Coach, and I don’t think I’m going to give away any spoilers in sharing that he has assisted her in her daily diabetes management that goes beyond what a continuous glucose monitor can do.

And here’s why I love this book: this is not a “…and they all lived happily ever after.” Stephany doesn’t pollyanna this experience; she was reluctant to get a service dog.  Elle was denied by a camp director going back to a summer camp that she attended post-diagnosis before she got Coach. Elle still has diabetes. (Wait, is that a spoiler?)

The story is heavy on the Shaheen side of the family (they are a prominent family from NH; Stephany’s mother is a member of Congress and former Governor) and detracts from the story of Elle and Coach. (Elle’s dad has a brother with Type 1 diabetes, but after a few brief mentions, is excluded from the remainder of the book.) Not everyone gets to meet Dean Kamen and Michael J. Fox and other celebrities without the connections the Shaheen family developed through politics. The side stories were superfluous.

It also focuses solely on the early days of diagnosis with a young child. Even though the final words are written six years after Elle was diagnosed, very little is said about her life with diabetes now. How is she adjusting to being a teenager with diabetes? No burnout? How does a diabetes alert dog factor into dating? Not even a post-script from Elle. That was disappointing.

Elle & Coach is not about finding a cure for diabetes. It’s about finding what works until that cure is found. For Elle, it’s Coach.

My final thoughts: Go get a copy. I highly recommend it. Keep a box of tissues handy. You’ll need it.


Insulin for Life USA

9450799For many of us, the thought of not having insulin or testing supplies is…unthinkable. We know what happens and it’s not acceptable. There are many organizations that work throughout the world to help people with diabetes get the life-saving elixir and the needed supplies to those who would otherwise have nothing… and bluntly put… die without our help.

When I see people on social media ask where they can send unused insulin and supplies, I immediately think of Insulin for Life USA.

Who is Insulin for Life USA?

They are a not-for-profit organization located in Gainesville, FL. They collect unexpired and  unneeded insulin, test strips, and other diabetes supplies (think lancets!), and ship them to developing countries. They are then distributed, free of charge, to children and adults with diabetes who otherwise would go without these life saving medications.

What does Insulin for Life USA need?

Here’s the list.

They will accept insulin vials and pen cartridges, syringes and pen needles, glucagon kits, A1C kits, ketone sticks, new in box meters, strips, lancets, and unused lancing devices. You can pack your unused supplies and ship them to Insulin for Life USA and they’ll send you a tax-donation receipt. (I’ve done it. It’s super easy.) Here’s all the info…


Donation packing guide

Updated Shipping Label

Why Insulin for Life USA and not somewhere else?

Yes, I know that there are people in the US that need supplies. There are a ton of “pay it forward” groups on Facebook where people are asking for insulin or strips to help them get through. There are gaps in insurance or help right here in the US. (And I created the comprehensive list of programs and co-pay assistance for people in the US to get prescription medications and supplies because most people don’t even know about them!)


Imagine no pharmacies. No Wal-Marts. No cheap way to get a vial of Relion insulin, a meter and a few strips to tide you over.


Think about how you would feel.

This is why Insulin for Life USA exists. And if you have the ability to send a box of unused supplies to that person with diabetes to give them something…. please know that this option exists.

They’re on Facebook and posted this message yesterday:

You may recall in late August that Tropical Storm Erika devastated the small country of Dominica in the Caribbean.

Insulin for Life USA has been contacted by the International Diabetes Federation requesting that we send diabetes support to aid in the rebuilding process. We encourage those who would like to play a role in this emergency support and our ongoing efforts to assist those in need to consider making a donation.

You can become a part of our team either by donating insulin, test strips and other diabetes supplies or by making a financial contribution. All gifts to Insulin for Life USA are considered tax deductible by the IRS.

There are many worthy organizations. This is one of them. And they’re not asking for money (well, yes, they will take a monetary donation…), but if you have unused supplies…. this is the organization that can distribute them to those who have no access. 

And I’m all about that.

My Pregnancy Announcement

Ladies and gentlemen, boys and girls… big news.

This is my pregnancy announcement.


You shouldn’t be.

Women with T1 diabetes can have healthy babies. Healthy pregnancies. It can happen.

If you are a T1 family (of one or more, seeing as how I feel having a baby as a T1 involves more than just yourself…), join Glu on September 28th from 5:30 – 8:00pm.


Microsoft Word - Pregnancy Flyer FINAL.docx

Attending In Person

If you can attend in person, you’ll go here: 11 Avenue de Lafayette, Boston, MA after sending an email to: gluevents@myglu.org

Attending Virtually

They will be broadcasting it live through a super cool feature called blab.im. Register at the email above to get the details.

Want to get your questions answered?

Here is the link where you can submit questions up to a few hours before the event starts. https://blab.im/glu-t1d-exchange-type1-diabetes-and-pregnancy

I’m proof that T1s can have successful pregnancies and have amazing babies. There is so much bad information out there, so let’s change that. 


The Kid thinks this post is funny, because she is definitely going to be an only child (and she likes it that way.)

My pregnancy announcement is this:

No. I’m not pregnant. Seriously. 

Dear JDCA (Juvenile #Diabetes Cure Alliance) Part Two

hands-talking-1311915-640x480If you have no idea what’s going on, please read Dear JDCA Part One.

It will bring you up to speed (as quickly as 2500 words can), giving you the information regarding what the Juvenile Diabetes Cure Alliance thinks are the most likely “practical cures” for people with Type 1 diabetes and why their petition demanding JDRF and ADA to commit 30% of donations to “cure research” isn’t doing anything to help the diabetes community except cause deep fractures amongst us.

Part One covered the transplantation “practical cures” that JDCA believes we should all support with the intent to have these cures available by 2025.

Part Two below covers the devices and the immune system manipulation options they highlight.

Quick Recap

The Juvenile Diabetes Care Alliance states that they want a “practical cure” by 2025. JDCA’s Four categories of a “practical cure”:

  • Islet cell transplantation
  • A device that mimics the pancreas
  • Glucose-responsive insulin (“smart insulin”) ***Please note that none of the potential practical cures are of this type.***
  • Modification of the immune system (blocking, balancing, and/or retraining)

Every year, JDCA issues a report that tells potential donors which “practical cures” are more likely to pull ahead. Here are the 2014 “Potential Practical Cure Solutions,” found in the JDCA State of the Cure report. (2015 hasn’t been published yet, but expect it in the fall as in previous years).

For each,  I will provide you the basic info into what it is, where this is in terms of “potential” release into the community and who is funding it.

JDCA’s 2014 Potential Practical Cure Solutions (Part 2)


Bionic Pancreas (iLet)

Boston University

– Boston, MA

What it is: 

Engineers from Boston University have developed a bionic pancreas system that uses continuous glucose monitoring along with subcutaneous delivery of both rapid-acting insulin (to lower blood glucose) and glucagon (to raise blood glucose) as directed by a computer algorithm. The bionic pancreas automatically makes a new decision about insulin and glucagon dosing every five minutes; that’s 288 decisions per day, 7 days per week, 365 days per year. (Artificialpancreas.org)

Where it is in the pipeline of “practical cure”:

According to Clinical Trials.gov, Phase III clinical trials will begin soon, with an estimated completion date of August, 2016. 80 participants will be in this trial. All clinical trials to this date have had favorable results.

If the pipeline is followed, commercialization is to be expected by 2018. The major issues will be funding and the FDA approval of stable glucagon provided by Xeris Pharmaceuticals.


Who is funding this “practical cure”?

Drs. Damiano and Russell do not work for a privately funded company. They work for universities. Funding is obtained through NIH grants and generous donations from private donors. JDRF did fund a portion of this research. 

There is currently no investment funding for future commercial agreement. Funding is being obtained through donations made through Boston University and Massachusetts General Hospital, private grants, and potentially NIH.

This is one “potential cure” that is fueled by direct donations from the general public.

If you are interested in donating to the Bionic Pancreas (iLet), you can do so here. 

If you want to learn more about the iLet, click here.

Modification of the immune system


Faustman Labs (Massachusetts General Hospital)

-Boston, MA

What it is: 

The BCG Human Clinical Trial Program is testing Bacillus Calmette-Guérin (BCG), an inexpensive generic drug, as a treatment for advanced type 1 diabetes.

…current research focuses on discovering and developing new treatments for type 1 diabetes and other autoimmune diseases, including Crohn’s disease, lupus, scleroderma, rheumatoid arthritis, Sjögren’s syndrome, and multiple sclerosis. (Faustman Lab website)

Where it is in the pipeline of “practical cure”:

A Phase II clinical trial which will last five years is being launched.

In the phase I clinical trial, which was published in the August 8, 2012, issue of PLOS Medicine, two injections of BCG spaced four weeks apart led to temporary elimination of diabetes-causing T cells and provided evidence of a small, transient return of insulin secretion. The phase II clinical study will include more frequent dosing over a longer time period to determine the potential of repeat BCG vaccination to ameliorate the autoimmune state and improve clinical parameters such as HbA1c, a marker of average blood sugar control. (Eureka Alert)

Here is the Clinical Trials.gov posting for the Phase II Clinical Trial. Please note that this is a double blinded trial. Neither the investigator nor the participant will know if they are being administered the BCG vaccine or saline injections over 5 years. 150 participants will be selected.

Earliest results will be in 2020. Please also be aware that a Phase III Clinical Trial must be conducted after successful results are shown, which can delay commercialization by several years if the Phase II Clinical Trial results show promise.

Who is funding this “practical cure”?

The Lee Iacocca Foundation gave Faustman Labs $10 million dollars initial funding for her Phase I trials and has also committed funding to Phase II trials. Faustman Labs estimates that Phase II trials will cost $25.2 million dollars.

This is one “potential cure” that is fueled by direct donations from the general public.

If you are interested in donating to Faustman Labs, click here. 

Note: Mike Hoskins of DiabetesMine/Healthline did a recent interview with Dr. Denise Faustman in March, 2015. It’s an important read.  During the interview, Dr. Faustman mentions that neither JDRF or Helmsley Charitable Trust has funded her, but that NIH, private supporters, Lee Ioacocca and others have chosen her research as their “practical cure.”


Tolerion, Inc.

-Portola Valley, CA

What it is: 

TOL-3021, is a novel reverse vaccine that induces tolerance to the type 1 diabetes specific auto antigen proinsulin and thereby reduces disease activity.

Unlike conventional vaccines, which act to stimulate the immune system, the reverse vaccine TOL-3021 is designed to selectively suppress specific elements of the immune system that are inappropriately activated in type 1 diabetes. TOL-3021 contains an engineered DNA plasmid that expresses proinsulin, which is associated with the autoimmune-caused destruction characterizing type 1 diabetes.(Tolerion website)

Where it is in the pipeline of “practical cure”:

In 2013, a press release regarding TOL-3021 stated:

The Phase 2 study results reported in today’s edition of Science Translational Medicine1 demonstrated that TOL-3021 preserved pancreatic beta-cell function while reducing destructive disease-specific T-cell activity in patients with type 1 diabetes.

These promising Phase 2 data indicate that TOL-3021 may stop the destruction of pancreatic beta cells and improve the long-term outlook for patients with type 1 diabetes, even in adults with long-established disease. Based on these results, we are eager to test TOL-3021 in a larger trial with longer dosing beyond 12 weeks, and to assess whether it might slow or stop disease progression entirely in younger patients when administered before large numbers of beta calls have been destroyed.

Nothing in regards to clinical trials has been published since 2013. In 2013, an article regarding the Stanford researchers who conducted this trial stated:

There are caveats with the trial. For one, the vaccine must be studied in more humans and is years away from being considered for Food and Drug Administration approval. What’s more, in the study, the vaccine’s benefits tailed off a few weeks after its 12-week dosing schedule was stopped.

I have yet to find another announcement regarding a Phase III clinical trial or anything regarding this “practical cure” since 2013. 

Who is funding this “practical cure”?

Dr. Lawrence Steinman, the Stanford researcher who, along with other researchers involved with this project, founded Tolerion. Here’s what he had to say regarding funding:

I can’t give enough praise to Bayhill’s investors, the JDRF (formerly the Juvenile Diabetes Research Foundation) and well-known VCs on Sand Hill Road and the Bay Area.

(When I dug a little deeper, I found that the original name of this drug was BHT-3021 and the trial was funded by… JDRF in collaboration with Bayhill Therapeutics.)

Rights to the reverse vaccine technology and associated product pipeline have been licensed to Tolerion by Stanford University.

There is no public donation funding being requested.

Cyclosporine Omeprazole/Lansoprazole

Perle Bioscience

-Charleston, NC

What it is: 

Cyclosporine is a well-known immunosuppressant given as an anti-rejection medication after organ transplantation and for treatment of RA (rheumatoid arthritis) or psoriasis.

Lansoprazole is a proton-pump inhibitor. You might know it by its brand name: Prevacid.Omeprazole is also a proton-pump inhibitor. (Brand name: Prilosec.) It decreases the amount of acid in the stomach and is commonly used in treating heartburn and GERD (reflux).

In 2013, Chris Leach of Insulin Nation wrote an incredibly informative article about Perle Bioscience and their “practical cure”.  He gave a better overview than I ever could about this so I encourage you to read his work.

Where it is in the pipeline of “practical cure”:

On June 23, 2015, Perle Bioscience announced that a Stage 3 clinical trial was beginning with their drug combination – PRL001. Except…

This Phase III clinical trial is not for individuals with long-standing Type 1 diabetes. According to the ClinicalTrial.gov information, this trial is for newly diagnosed Type 1 diabetics aged 10 – 20 years old. The trials will not be conducted in the U.S.

For those with diabetes diagnosed more than 12 weeks ago, the only clinical trial data listed on ClinicalTrial.gov, there is simply a “This study is not yet open for participant recruitment.” It’s last update was October 3, 2013.

Perle Bioscience’s website gives this information regarding its pipeline:


PRL001 consists of the combination of two previously approved therapeutic agents, each yielding their specific response on the body. In Vivo animal studies, the first product inside of PRL001 causes the regeneration of the patients own insulin producing pancreatic beta cells to start growing again. The second part of PRL001 lowers the body ability from re-attacking the newly formed insulin producing cells to essentially put the pancreas back to how it was functioning prior to diabetes. Both agents are taken orally and no injections are needed for this product. Perle Bioscience, Inc. holds the issued and pending US and IPC patents (see below for patents) for the new use of these agents in treating diabetes. PRL001 is starting multi-center Phase 3 human trials in early 2015.


PRL002 is a novel peptide developed by Perle Bioscience, Inc., where in current in vitro and in vivo studies, is showing signs of high levels of regeneration of insulin producing pancreatic cells. PRL002 is made up of our novel Beta Regeneration Agent for Diabetes (BRAD) peptides. Currently PRL002 is in animal trials with the hope to have an IND application to the FDA in early 2016. Our hope is that PRL002 will be used for both type 1 and type 2 diabetes. Please sign up for our newsletter to stay up to date on our progress (signup from the bottom of any page).

There is no mention of the Phase III clinical trial for individuals with “existing Type 1 diabetes” on Perle Bioscience’s website. 

Who is funding this “practical cure”?

According to Motley Fool:

Perle is a privately held company, so no investments can be made here as of yet.

Tianhe Stem Cell Biotechnologies

Stem Cell Educator Therapy


What it is: 

“Stem Cell Educator therapy” is the innovative technology developed by Dr. Yong Zhao that uses stem cells drawn from human cord blood to targets autoimmune diseases. Currently, Tianhe is focusing on the application of Stem Cell Educator therapy in diabetes. Our clinical data provide powerful evidence that Stem Cell Educator therapy can balance the immune system and lead to the regeneration of islet beta cells and improve metabolic control in long-standing diabetic subjects. This groundbreaking technology is taking steps towards the ultimate cure of diabetes and revolutionizing the treatment of other autoimmune-related diseases.(Tianhe website.)

Where it is in the pipeline of “practical cure”:

Clinical Trials.gov gives this information: Stem Cell Educator Therapy in Type 1 Diabetes was last updated in November, 2013 and is still stating that it is recruiting participants in China and Spain. Expected completion was September, 2014.

No additional information regarding trials and a “practical cure” has been listed on the Tianhe website. The latest clinical trial information discusses Stem Cell Educator Therapy for hair regrowth in Alopecia Areata patients. (April 22, 2015)

Who is funding this “practical cure”?

The Chinese government, according to the sponsorship information provided on Clinical Trials.gov. The Tianhe website is looking for investors, stating this as an enticement:

A huge marketing opportunity due to the global prevalence of diabetes: For instance, the total number of Americans living with diabetes will increase by 64% in 2025. Annual Medicare cost will increase by 72%, with $514 billion/year (72nd ADA report).

There is no request from the general public for donations.

Previous JDCA “Practical Cures”

file-1-3-1237622-640x640JDCA has published three reports, talking about the “cure” and which projects they believe fall under the guidelines. I’ve focused on the 2014 report (which is the latest), but what about 2013? 2012? (They began in 2011.)


In 2013, here’s what they said were practical cures paths, because they were in human trials:

Still going…

Diabecell (Phase II) – I’ve listed the latest in Part 1.

Tianhe Stem Cell Educator Therapy (Phase II) – I’ve listed the latest above.

BCG (Phase II recruiting) – I’ve listed the latest above.

ViaCyte (Phase I) – I’ve listed the latest in Part 1.

Off the list in 2014…

Sitagliptin/Lansoprazole (Phase II) Note: collaborator listed on ClinicalTrials.gov is JDRF. Status listed now as “The recruitment status of this study is unknown because the information has not been verified recently. )

Monolayer Cellular Device (Phase 1) According to ClinicalTrials.gov, this study is still recruiting patients for one location in Belgium, but JDCA has dropped it from the 2014 list of practical cures.


In 2012, here’s what they said were practical cures paths:

Still going…

Diabecell (Phase II) – I’ve listed the latest in Part 1.

BCG (Phase II recruiting) – I’ve listed the latest above.

Off the list in 2013 and 2014…


Monolayer Cellular Device

ATG/GCSF – This Phase II clinical trial  is no longer recruiting patients but is active (meaning they got enough participants). The work is still ongoing, but if you read the criteria, it was modified to say that the participants must have been diagnosed between 1 and 2 years before the start of the study, taking out the possibility for those with long-standing Type 1 to participate. The trial is called: Reversing Type 1 Diabetes After it is Established and is being run by University of Florida with grants from the Helmsley Charitable Trust and Genzyme.

My Scorecard for 2014 Practical Cures

Based on what JDCA says are “practical cures” and what I’ve researched, here is the likelihood that they will become commercially available by JDCA’s 2025 “deadline.”


VIACYTE – Phase I/II clinical trial right now. Estimated commercialization date of this product if Phase I/II is successful, a Phase III trial is conducted and successful and proceeds to FDA approval? Unlikely by 2025.  
DIABECELL – Phase I/IIa completed. No Phase III clinical trials listed in ClinicalTrials.gov. Estimated commercialization date of this product if there is a Phase III trial and it proceeds to FDA approval? Unlikely by 2025.
ßAIR BIO-ARTIFICIAL PANCREAS – Phase I/II clinical trial right now. Estimated commercialization date of this product if Phase I/II is successful, Phase III happens and is successful and proceeds to FDA approval? Unlikely by 2025.


BIONIC PANCREAS (iLET) – Phase I/II completed and Phase III beginning soon. Estimated commercialization date of this product if  Phase III proceeds to FDA approval and Xeris Pharmaceuticals gets FDA approval for stable glucagon? Likely by 2018 (2019 if you’re hedging bets.).

Modification of the Immune System

BCG – Phase II clinical trial being launched, lasting five years. Estimated commercialization date of this product if Phase II and Phase III is successful, proceeding to FDA approval? Unlikely by 2025.
TOL-3021 – Phase II clinical trial completed, with results showing the benefits did not last longer than the 12 week dosing period. There are no Phase III clinical trials list. Unlikely by 2025.
CYCLOSPORINE/LANSOPRAZOLE – Phase II completed. No clinical Phase III clinical trial listed on clinicaltrials.gov for patients with existing Type 1 diabetes. Unlikely by 2025.
STEM CELL EDUCATOR THERAPY – Phase II clinical trial listed in 2013 and still recruiting. Estimated commercialization date of this product if Phase I/II is successful, a Phase III trial is conducted and successful and proceeds to FDA approval? Unlikely by 2025.  

Conclusion to this LONG Part 2…

paper-numbers-1236363-639x426What one organization thinks is a  cure isn’t always a cure to you. It’s easy for JDCA call out an organization for not doing enough for what they think is “cure research.”
It’s much more difficult to do so when you realize that everyone has a different (and in JDCA’s reports, showing an ever changing) idea of what a “practical cure” would mean. 
What is practical in 2012, 2013, and 2014 may not be practical in 2015. JDCA kept mentioning DRI’s BioHub, but never put it on the top list of their “practical cures,” but yesterday’s announcement that the first human subject to be implanted with the BioHub is off insulin. (Time will tell is this is successful in the long-term, but JDCA didn’t consider this a donation priority.)
What about “smart insulin?” What about the other closed loop AP trials? What about…. something we haven’t thought of yet? We don’t know what the young researchers in five years will present to major diabetes organizations (or the general public). Seed money comes from these large diabetes non-profits to new researchers who seek out grants to get them off the ground. What happens to these researchers if they don’t get the seed money?
Nothing. Literally. 
JDCA is cherry-picking (and finger pointing, but to what end remains to be seen). It’s their right and I’ve learned a lot about the different avenues to a “practical cure. ” (Hat tip to JDCA for sending me down the rabbit hole. I’m certainly better educated for it.)
We are ALL cherry-picking. It’s our right. But do it by doing the research and making smart, educated choices.
We are all in this together, despite differences in opinions about what a cure entails, who is going to provide it, and who should fund it. And most importantly, who speaks for you. (Here’s a hint… it’s not me or JDCA.) It’s my hope that you learned something about “cure research” and where YOU can get your information about cure pipelines so you can speak for yourself.
Thank you for reading all the way to the end.